Skip to content
Kanda Software Logo
The Future of Drug Development Runs on Omics Data Platforms image
August 27, 2025
Life Sciences

The Future of Drug Development Runs on Omics Data Platforms

Traditional drug development is running into a serious efficiency problem.
Getting a new medicine to market now takes more than ten years and costs well
over $2 billion on average, according to a recent study. Even
though
scientific breakthroughs keep arriving, the expense of R&D
keeps climbing faster than the number of new approvals, a paradox often called
“Eroom’s Law.” The old model, with its long timelines and high drop-out rates,
is
becoming hard to justify.

The industry must find a different way to meet the expectations of
personalized treatment and to tackle diseases that involve many moving parts.
Relying on the classic playbook won’t get us there. What we need is a strategy
that leans on data and embraces the full complexity of human biology. Omics
data platforms supply the technical backbone that can turn huge biological
data sets into therapies that actually help patients.

annual R&D spending drug development

Source: Congressional Budget Office

Why does drug development demand a new approach?

The “one-size-fits-all” view of medicine is losing relevance.

Precision medicine
and targeted therapies demand a deeper look at the molecular roots of disease.
Most illnesses are not caused by a single faulty molecule; they arise from a
tangled network of genes, proteins, and metabolites. Traditional research
methods often miss this web, which leads to drug candidates that stumble in
clinical trials because they either don’t work well enough or raise unexpected
safety concerns.

Multi-omics, the combining of genomics, transcriptomics, proteomics and
metabolomics, offers a way forward.A review in Proteomes
points out that this integrated view gives a more complete picture of
biological systems, moving past the limits of studies that focus on just one
layer. By stacking different types of data, scientists can pinpoint drug
targets with greater precision, sort patients into more meaningful groups, and
forecast how treatments will perform.

What are omics data platforms and how do they reshape research?

Think of the human body as a bustling city. As this Medium article
puts it, Genomics is the master plan for every building, transcriptomics shows
which plans are being used right now, proteomics describes the workers and
machines inside those structures, and metabolomics tracks the resources
flowing through the streets.

The promise of this information is huge, but the sheer volume, variety, and
intricacy create massive obstacles. Data points are often scattered across
separate systems, lack consistent metadata, and come in formats that don’t
talk to each other. Pulling useful, cross-functional insights from such a mess
is almost impossible.

An omics data platform is the infrastructure that brings order to the chaos.
It is more than a storage vault; it is an integrated environment that can
ingest, process, and analyze multi-omics data at scale. The platform supplies
a toolbox that supports every step of drug discovery from loading raw files to
generating actionable insights. Its ultimate aim is to become a single source
of truth that makes complex data findable, accessible, interoperable, and
reusable (FAIR).

multi omics interactions

Overview of multi-omics interactions and how genome-first vs phenotype-first
starting points shape analysis.
Source: Front Line Genomics

How Omics Platforms Speed Up Discovery and Deliver Returns

By gathering and harmonizing tangled biological data, omics platforms attack
the core inefficiencies of the old R&D pipeline. They shave time off
projects, raise the quality of candidate molecules, and cut the financial risk
of late-stage failures.

Revolutionizing Target Identification and Validation

The first stage
of drug discovery is to
locate a molecular target, which is a gene or protein
linked to a disease. In the past, researchers manually combed through
literature to find these clues. Modern omics platforms, especially when paired
with AI and machine learning, automate and deepen that hunt. An article in Quantitative
Biology

shows that AI can sift through multi-omics data, spotting patterns and
relationships that are invisible to the human eye, and then suggest novel
biomarkers and drug targets.

By merging genomic, transcriptomic and proteomic information, teams
can:

  • Boost confidence in targets:
    Overlapping signals across layers give stronger proof that a target truly
    drives the disease.
  • Lower false positives: Cross-validation across data types filters out noise,
    making findings more
    reliable.
  • Reveal complex mechanisms: The analysis can map how genetic changes ripple through
    proteins and
    metabolic pathways, offering a fuller view of disease biology.

Economic Impact: Cutting Costs and Shortening Timelines

Most of the money spent on drug development goes into clinical trials, and a
failure at that stage can be financially devastating. Improving the quality of
candidates before they reach patients can dramatically lower those failure
rates. An analysis by PharmTech
estimates that a 20 % drop in clinical-phase failures could save hundreds of
millions of dollars for each approved drug.

R&D costs per new medicine at major biopharma companies

R&D costs per new medicine at major biopharma companies climbed from
roughly $1.4 billion to $2 billion between 2010 and 2019. 
Source: Frontiers

Companies that have adopted these technologies are also moving faster.
AI-first startups have shown they can push molecules into clinical testing in
a fraction of the usual time. For instance, Deep Genomics
identified a new target and candidate for Wilson’s disease in under 18 months,
a timeline that would normally span several years. Faster progress means lower
development costs and a quicker route to market.

A Real-World Example: Kanda’s Platform for a Large Pharma Partner

Building a truly useful omics platform is a complex project. To illustrate
what success looks like, consider the end-to-end analytics platform Kanda
recently delivered for a major pharmaceutical client. The partner struggled
with hundreds of reference datasets spread across many locations, which slowed
decision-making.

Kanda’s solution was a unified system built around four custom components,
each designed to create a single, standardized data ecosystem:

Annotator

Replaces manual, error-prone tagging with an automated workflow. By
centralizing metadata under a controlled vocabulary, it guarantees that every
dataset is consistent, searchable and ready for integration.

Visualization Platform

A web-based, interactive app that lets scientists explore complex data
through heatmaps, network graphs and other visual tools. Turning raw numbers
into clear pictures helps generate new hypotheses quickly.

Data Transfer Manager

A user-friendly web application that automates secure exchanges with external
labs. It enforces best-practice protocols, reduces mistakes and eases the
burden on data managers.

Single-Cell Data Tracker

Maintains a real-time catalog of publicly available and internally generated
single-cell datasets. It continuously aggregates new data and intelligently
merges duplicates, saving time and preventing redundancy.

The result was a
cohesive, standardized data
environment that gave the client
deeper insights and a faster research workflow.

Overcoming Common Hurdles: Integration, Security and Scale

The promise of omics platforms is clear, but putting them into practice
brings several challenges. Legacy systems must be linked, data privacy must be
protected, and the architecture has to grow with ever-larger datasets.

Data fragmentation remains the biggest obstacle. The Institute for
Experiential AI

notes that silos hide valuable patterns and make it hard to reproduce or scale
findings. A successful platform must not only gather data but also harmonize
it, standardizing formats and applying consistent metadata throughout.

Security and compliance are non-negotiable. Omics data often includes
sensitive patient information, so platforms need robust access controls and
must meet regulations such as HIPAA and GDPR.

Scalability is essential as data volumes explode. Cloud-based services like

Amazon Omics
are emerging to provide flexible, on-demand infrastructure that can store and
analyze petabytes without the overhead of managing physical hardware. Kanda
has extensive experience building secure, scalable digital health solutions
that meet these demands.

how amazon omics works

Amazon Omics: How it works across storage, workflows, and analytics.
Source: AWS

What does the next decade of drug development hold?

The marriage of omics platforms and artificial intelligence is set to reshape
the industry further. AI and machine learning are no longer buzzwords; they
are practical tools for extracting meaning from high-dimensional data. We are
already seeing a shift from basic machine learning models to deep learning
architectures that can capture nonlinear relationships across multi-omics
layers, producing more accurate predictions of disease risk and treatment
response.

Advances in AI for clinical image analysis
and natural language processing will also matter. By linking unstructured data
such as physician notes and scientific papers with structured omics
information, researchers will obtain a truly comprehensive view of each
patient. As these healthcare software development trends
continue, the drug development lifecycle will become faster, more precise, and
more productive.

How Kanda Can Help

Designing, building and rolling out a custom omics data platform involves many
moving parts: merging old systems, guaranteeing security, and reconciling
inconsistent data formats. These tasks require deep technical expertise and
strategic planning, resources that many life science organizations find hard to
allocate. Partnering with a team that specializes in custom software development
can bridge that gap.

  • Build Custom Omics Platforms: We design and implement secure, scalable, compliant
    platforms that manage
    the full lifecycle of multi-omics data.
  • Manage Legacy System Integration: We create robust transformation pipelines that
    harmonize siloed datasets
    and bridge old infrastructure with modern analytics.
  • Develop Interoperable Applications: We build intuitive tools from annotation
    utilities to advanced
    visualization dashboards so scientists can explore data and move discovery
    forward.
  • Ensure Security and Compliance: We engineer to meet regulations like HIPAA and
    GDPR, with access controls
    and safeguards that protect sensitive biological and patient data.

Talk to our
experts

to learn how a tailored omics platform can transform your drug-discovery
workflow, turning massive data sets into the next generation of precision
therapies.

Conclusion

Turning the complexity of human biology into effective treatments is the next
big unlock. The linear R&D model isn’t built for that job. Omics data
platforms make the shift possible by grounding discovery in integrated data
and analytics. With multi-omics and AI working together, teams can find better
targets, design stronger candidates, and move through development with fewer
surprises.

For pharma and biotech, the question isn’t whether to adopt this approach but
how to implement it well. The advantage goes to organizations that can bridge
legacy systems to a modern, integrated data environment while keeping that
environment usable, secure, and scalable as the science moves forward.

Related Articles